Sengenics is a proteomics company with a unique technology used to produce full-length, correctly folded, and functional proteins. The technology is leveraged to support pharma and academic research to advance precision medicine through an increased understanding of the autoimmune response in humans. Sengenics is currently focused on measurement of autoantibodies for applications in autoimmune diseases, oncology, neurological conditions, and infectious disease.
Sengenics
Overview
Sengenics at a glance
Key developments 2022
2nd half of 2022 was characterized by the appointment of a high caliber CEO, Jerry Williamson. Sengenics continued to serve customers globally, with an increased focus on large pharma customers, who deploy the KREX technology over various use cases and therapeutic indications. Earlier in the year, the company launched the Pan-Autoimmune product, a new protein array service.
Sector
Life science
Location
United States and Malaysia
SDG aligment
Environmental
Carbon intensity: Tons CO₂e per EUR m revenue
Total tons CO₂ emitted
Change from '21-'22
2022
+0%
1 227
2021
946
2020
469
Monetized climate impact
EURm
The figure represents the monetized value the company has on the environment. See chapter 4 for methodology.
Social
Full time employees
Summa staff turnover rate31%
Unadjusted gender pay gap72%
Gender balance, % females
%
Board
%
Management
%
All employees
Monetized employment impact
EURm
The figure represents the monetized value the company has as a quality employer. See chapter 4 for methodology.
Governance
Via Summa Compliance
%
✔ Code of conduct
✔ Supplier code of conduct
✔ Economic Sanctions
✘ Competition Law/Antitrust
✔ Data Protection/IT Security
✔ Anti-curruption
✔ Whistleblower
Science Based Targets
Sengenics committed to Science Based Targets in 2022 and received target validation Q1 2023. The company commits to reduce scope 1 and 2 GHG emissions by 42% by 2030 from a 2021 base year, and to measure and reduce scope 3 emissions.
Board gender diversity
The company is continuously working to improve gender diversity towards 40% and several replacements have been made in 2022. Most notably, compared to last year, one board member was replaced with Dr. Yvonne Linney. In addition, CEO Jerry Williamson was also appointed as a member of the board.
What are the challenges Sengenics addresses?
0%
of patients receive no benefit from treatment with top 10 best-selling drugs in the world
0%
of OECD GDP is spent on healthcare
How does Sengenics help?
Reality today
We do not understand the biology of many leading diseases and lack appropriate biomarkers, preventing us from developing effective medication and delivering precision treatment.
Sengenics approach
Sengenics proteomics technology enables biological response research at unrivalled sensitivity and specificity, helping develop more targeted, effective, and efficient diagnostics and therapies.
Aspirational future
Deeper understanding of human biology and disease allows us to develop and deliver the most effective diagnostics and treatments for patients.
What impact does Sengenics create?
Accumulated no. of publications
Change from '21-'22
2029 target: 120
2022
+0%
40
2021
31
2020
23
Data points generated
Change from '21-'22
2029 target: 253
2022
+0%
12m
2021
9m
2020
6m
Number of samples profiled
Change from '21-'22
2029 target: 47 012
2022
+0%
4 833
2021
4 090
2020
2 005
Who is impacted?
Researchers are impacted directly through more effective tools to understand human biology. Patients are impacted indirectly through breakthroughs in treatments.
What are the impact considerations?
Additionality
Sengenics unique technology and collaborative partnerships with top biopharma companies is driving forward precise, cost-effective research that would not otherwise be possible.
Risks
Sengenics impact depends in part on how its customers in biopharma choose to use its tools. Product quality is also fundamentally important, enabling reproducibility in research and precise, safe innovation in therapies.